The Business Times
SUBSCRIBERS

Samsung Biologics aims to raise 2.25t won in IPO

Published Tue, Oct 4, 2016 · 09:50 PM

Seoul

SAMSUNG Biologics Co is seeking to raise as much as 2.25 trillion won (S$2.77 billion) from a South Korean initial public offering, taking an important step towards its goal of becoming the world's largest contract manufacturer of biological medicines.

The drug-making arm of the South Korean conglomerate will offer about 16.5 million shares at 113,000- 136,000 won apiece, according to a filing on Tuesday. Samsung Biologics will gauge demand for the share sale from Oct 26 to 27 with a final price to be announced on Oct 28.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here